As early as next year, medical marijuana could be sold as over-the-counter drugs at pharmacies across Australia
The Australian Medical Administration (TGA) has said it intends to make marijuana diphenol (CBD) available without a doctor's prescription.
The ad hoc decision by the drug administration would mean that the patient only had to inform a pharmacist that he needed medical marijuana, who could sell marijuana diphenols to the patient.
The decision by the Medical marijuana Authority is one of the biggest developments in the medical marijuana industry so far, said Josh Fegan, president of Medical marijuana Suppliers and Inc.
"This interim decision represents the greatest change in the attitude of Australian society and government towards medical marijuana since the adoption of the legislation in late 2016, which has transformed it from an marginal alternative drug to an alternative drug acceptable to mainstream society ," he said. "
Since its inception, Althrea has been a strong advocate for patient access to medical marijuana, and has closely followed the proposed amendments and participated in the consultation process. "
"We are excited about the FDA's decision to temporarily relax relax temporarily on marijuana products and see this development as a major step in Australia's over-the-counter development of pharmaceutical marijuana products. "
Fogang alleged that the product required a registration process involving safety and quality inspections.
He said marijuana products should be available by 2021.
Although marijuana diphenol will become an over-the-counter drug, it will be subject to some restrictions, including a maximum daily dose of 60 mg and a limit of 30 days of supply.
Any marijuana diphenol product is also allowed only through the mouth.
